DK1651247T3 - Behandling og diagnose af neoplasmer ved anvendelse af Thymic Stromal Lymphopoietin - Google Patents

Behandling og diagnose af neoplasmer ved anvendelse af Thymic Stromal Lymphopoietin

Info

Publication number
DK1651247T3
DK1651247T3 DK04778434T DK04778434T DK1651247T3 DK 1651247 T3 DK1651247 T3 DK 1651247T3 DK 04778434 T DK04778434 T DK 04778434T DK 04778434 T DK04778434 T DK 04778434T DK 1651247 T3 DK1651247 T3 DK 1651247T3
Authority
DK
Denmark
Prior art keywords
treatment
neoplasms
diagnosis
thymic stromal
stromal lymphopoietin
Prior art date
Application number
DK04778434T
Other languages
English (en)
Inventor
Martin Oft
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DK1651247T3 publication Critical patent/DK1651247T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK04778434T 2003-07-18 2004-07-16 Behandling og diagnose af neoplasmer ved anvendelse af Thymic Stromal Lymphopoietin DK1651247T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48826303P 2003-07-18 2003-07-18
PCT/US2004/022928 WO2005007186A1 (en) 2003-07-18 2004-07-16 Treatment and diagnosis of neoplasms using thymic stromal lymphopoietin

Publications (1)

Publication Number Publication Date
DK1651247T3 true DK1651247T3 (da) 2009-01-12

Family

ID=34079411

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04778434T DK1651247T3 (da) 2003-07-18 2004-07-16 Behandling og diagnose af neoplasmer ved anvendelse af Thymic Stromal Lymphopoietin

Country Status (17)

Country Link
US (3) US20050048061A1 (da)
EP (1) EP1651247B1 (da)
JP (3) JP5436753B2 (da)
AT (1) ATE407691T1 (da)
AU (1) AU2004257781B2 (da)
CA (1) CA2532595A1 (da)
CY (1) CY1108645T1 (da)
DE (1) DE602004016522D1 (da)
DK (1) DK1651247T3 (da)
ES (1) ES2313076T3 (da)
HR (1) HRP20080617T3 (da)
MX (1) MXPA06000659A (da)
NZ (1) NZ544456A (da)
PL (1) PL1651247T3 (da)
PT (1) PT1651247E (da)
SI (1) SI1651247T1 (da)
WO (1) WO2005007186A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2349762C (en) 1998-11-13 2013-12-24 Immunex Corporation Human tslp dna and polypeptides
US7288633B2 (en) 2001-07-23 2007-10-30 Immunex Corporation Modified human thymic stromal lymphopoietin
DK1651247T3 (da) * 2003-07-18 2009-01-12 Schering Corp Behandling og diagnose af neoplasmer ved anvendelse af Thymic Stromal Lymphopoietin
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
SE532251C2 (sv) * 2006-11-28 2009-11-24 Theravac Pharmaceuticals Ab Nya formuleringar av TSLP för behandling av TH2-medierade inflammatoriska sjukdomar genom vaccinering
KR101525631B1 (ko) * 2006-12-14 2015-06-04 엠에스디 인터내셔널 홀딩즈 게엠베하 개 흉선 간질 림포포이에틴 단백질 및 이의 용도
EP2170957A1 (en) * 2007-06-20 2010-04-07 Irm, Llc Methods and compositions for treating allergic diseases
US7982016B2 (en) * 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
EP2213682A1 (en) 2009-01-30 2010-08-04 Institut Curie TSLP promotes immune evasion and persistence of viruses
GB0918782D0 (en) * 2009-10-26 2009-12-09 St Georges Hosp Medical School A protein as an adjuvant for a vaccine
JPWO2012001889A1 (ja) * 2010-06-28 2013-08-22 国立大学法人東北大学 Ｔｓｌｐを恒常的に高発現する細胞、及び前記細胞を利用したｔｓｌｐ調節剤のスクリーニング方法
US20120020960A1 (en) * 2010-07-26 2012-01-26 Baylor Research Institute Thymic Stromal Lymphopoietin (TSLP) and OX40 Ligand in Cancer
US20160052985A1 (en) 2013-04-04 2016-02-25 Ieo - Istituto Europeo Di Oncologia Srl Thymic stromal lymphopoietin fragments and uses thereof
WO2018156649A1 (en) * 2017-02-22 2018-08-30 Flagship Pioneering, Inc. Compositions of t cell modulator (tcm) molecules and uses thereof
JP7239181B2 (ja) * 2017-04-04 2023-03-14 ロマ リンダ ユニヴァーシティ 癌治療のための生物製剤

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
EP1115867A1 (en) 1998-09-21 2001-07-18 Schering Corporation Human interleukin-b50. therapeutic uses
US20030099947A1 (en) * 1998-09-21 2003-05-29 Bazan J. Fernando Mammalian cytokines; related reagents and methods
CA2349762C (en) * 1998-11-13 2013-12-24 Immunex Corporation Human tslp dna and polypeptides
WO2002000724A2 (en) * 2000-06-28 2002-01-03 Amgen, Inc. Thymic stromal lymphopoietin receptor molecules and uses thereof
US6890734B2 (en) 2000-11-10 2005-05-10 Schering Corporation Nucleic acids encoding a cytokine receptor complex
EP1661986A1 (en) * 2000-11-17 2006-05-31 Nuvelo, Inc. Nucleic acids and polypeptides enocoded thereby that are member of the kallikrein gene familyNovel nucleic acids and polypeptides
CN1234728C (zh) * 2001-05-16 2006-01-04 上海睿星基因技术有限公司 新的人淋巴因子、其编码序列及用途
US7288633B2 (en) * 2001-07-23 2007-10-30 Immunex Corporation Modified human thymic stromal lymphopoietin
MXPA04007426A (es) 2002-02-01 2004-10-11 Schering Corp Usos de citosina de mamifero; reactivos relacionados.
US20040022813A1 (en) * 2002-08-05 2004-02-05 Jean-Claude Bystryn Shed antigen vaccine with dendritic cells adjuvant
DK1651247T3 (da) * 2003-07-18 2009-01-12 Schering Corp Behandling og diagnose af neoplasmer ved anvendelse af Thymic Stromal Lymphopoietin

Also Published As

Publication number Publication date
ATE407691T1 (de) 2008-09-15
US20050048061A1 (en) 2005-03-03
JP2007314547A (ja) 2007-12-06
EP1651247A1 (en) 2006-05-03
SI1651247T1 (sl) 2009-02-28
PL1651247T3 (pl) 2009-04-30
NZ544456A (en) 2009-02-28
US20140370025A1 (en) 2014-12-18
US20100015132A1 (en) 2010-01-21
WO2005007186A1 (en) 2005-01-27
US8822405B2 (en) 2014-09-02
JP5436753B2 (ja) 2014-03-05
JP2011236252A (ja) 2011-11-24
CA2532595A1 (en) 2005-01-27
DE602004016522D1 (de) 2008-10-23
HRP20080617T3 (en) 2009-01-31
PT1651247E (pt) 2008-12-15
CY1108645T1 (el) 2014-04-09
AU2004257781B2 (en) 2009-07-16
ES2313076T3 (es) 2009-03-01
MXPA06000659A (es) 2006-03-30
JP2007534623A (ja) 2007-11-29
AU2004257781A1 (en) 2005-01-27
EP1651247B1 (en) 2008-09-10

Similar Documents

Publication Publication Date Title
HRP20080617T3 (en) Treatment and diagnosis of neoplasms using thymic stromal lymphopoietin
DK1601694T3 (da) Anvendelser af IL23-antagonister, relaterede reagenser
UY28598A1 (es) Antagonistas de receptores de acetilcolina muscarinicos
EA200702278A1 (ru) Антитела, специфичные в отношении tgf-бета 1
DK1960434T3 (da) Monoklonale, humane antistoffer mod Fucosyl-GM1 og fremgangsmåder til anvendelse af anti-Fucosyl-GM1
DK2135881T3 (da) Antistoffer, som binder til det tumor-associerede antigen TAT10772, til diagnose og behandling af tumor
DE602005015397D1 (de) Leuchtstoff, Verfahren zu seiner Herstellung und diesen Leuchtstoff verwendende Lichtquelle
ECSP066940A (es) Antagonistas del receptor de acetilcolina muscarínico
DK1675623T3 (da) Ubiquitin eller gammakrystallinske konjugater til brug i terapi, diagnose og kromatografi
DK2573166T3 (da) Fremgangsmåder til fremstilling af T-celler til celleterapi
ATE514682T1 (de) 4-5-diamino-n,n-dihydro-pyrazol-3-on-derivate und deren verwendung als färbemittel für keratinfasern
NO20060777L (no) Muskarine acetylkolinreseptorantagonister
EA200801414A1 (ru) Кальцилитические соединения
DK1954713T3 (da) Modificerede grønfluorescerende proteiner og fremgangsmåder til anvendelse af samme
FI20040970A (fi) Laitteisto solujen kuvaamiseksi
DK1643884T3 (da) Apparat og fremgangsmåde til udtagning af granatæblekerner fra granatæbler
DK1768691T3 (da) Aequorinholdige præparater og fremgangsmåder til anvendelse af samme
NO20050962D0 (no) Fremgangsmate, system og kilde for implementering av flerbruker oppkobling
UY28567A1 (es) Antagonistas de receptores de acetilcolina muscarinicos
ITTO20030032A1 (it) Membrana permeabile selettivamente ai gas e metodo per la sua realizzazione.
NO20082238L (no) Lighteranordning med strømningsbegrenser og fremgangsmåte for å produsere og teste den samme.
NO20045705L (no) Apparat, saerlig til bruk ved laparoskopisk kirurgisk inngrep
DE602006010187D1 (de) Einzelsequenzhybridisierungssonden
NO20042767D0 (no) Sammenforingssystem, enkeltelementer og fremgangsmate for bruk av dette
ITTO20040345A1 (it) Apparecchio di prova per l'esecuzione di prove hdt e vicat.